Well, hello, hello, guys, you're listening to Beauty Bites with Dr. K, Secrets of a Plastic Surgeon,

and it's time for a five-minute Friday. I'm going to talk aboutites with Dr. K, Secrets of a Plastic Surgeon, and it's time for a five-minute

Friday.

I'm going to talk about Ozempic because, well, actually, guess what, OZemphic is about to be old

news.

According to an article in the Atlantic Monthly, a great article written by Yasmin

Tyag. There's a huge explosion written by Yasmin Tayag.

There's a huge explosion in obesity drugs on the horizon, and OZembek is about to be old news.

As you guys know from our previous podcasts, I love OZempic.

I like Wagovi, Monjaro.

These products definitely have an amazing role in shaping the future

health of America, getting rid of obesity, improving people's dependency on hypertension,

diabetes, drugs, and just really reteaching appetite to the body.

So these products belong to a class of medicines called GLP1 agonists,

and they've been around for several years, some of them close to 20 years. Remember these drugs,

the Ozempic class of drugs, they mimic the hormone, GLP1, the Glucagon-like peptide

1. Let me give you a little review, your physiology

review. They bind to its receptor in the body and that triggers a sense of fullness, that

feeling of fullness like you just ate. It also slows the release of food from the stomach.

It increases your insulin secretion, keeps your blood sugar in check.

That's why Ozempic was indicated for diabetes drug.

But you don't have to be diabetic to benefit from these anti-obesity drugs.

...